Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.
暂无分享,去创建一个
D. Silbergeld | D. Born | K. Swanson | C. Bridge | M. Mrugala | A. Hawkins-Daarud | B. Storer | R. Rockne | H. Kiem | Jennifer L. Gori | L. Gonzalez-Cuyar | J. Adair | A. Baldock | J. Rockhill | S. Johnston | B. Beard | Laura A Guyman
[1] Jin-xiang Cheng,et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in Elderly Glioblastoma Patients: A Meta-Analysis , 2014, PloS one.
[2] Kristin R. Swanson,et al. Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression. , 2013, Cancer research.
[3] Kristin R. Swanson,et al. Discriminating Survival Outcomes in Patients with Glioblastoma Using a Simulation-Based, Patient-Specific Response Metric , 2013, PloS one.
[4] D. Silbergeld,et al. Extended Survival of Glioblastoma Patients After Chemoprotective HSC Gene Therapy , 2012, Science Translational Medicine.
[5] E. Shaw,et al. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. , 2011, International journal of radiation oncology, biology, physics.
[6] H. Kiem,et al. Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. , 2010, The Journal of clinical investigation.
[7] K Hendrickson,et al. Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach , 2010, Physics in medicine and biology.
[8] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] T. Cloughesy,et al. Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. , 2009, Cancer research.
[10] Allan H Friedman,et al. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. , 2009, Neuro-oncology.
[11] Gargi Chakraborty,et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. , 2009, Cancer research.
[12] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[13] Allan H Friedman,et al. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J M Wardlaw,et al. Velocity of radial expansion of contrast-enhancing gliomas and the effectiveness of radiotherapy in individual patients: a proof of principle. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).
[15] K. Swanson,et al. A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle , 2007, British Journal of Cancer.
[16] Kristin R. Swanson,et al. The Evolution of Mathematical Modeling of Glioma Proliferation and Invasion , 2007, Journal of neuropathology and experimental neurology.
[17] H. Kiem,et al. Efficient transduction and engraftment of G-CSF-mobilized peripheral blood CD34+ cells in nonhuman primates using GALV-pseudotyped gammaretroviral vectors. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[18] Lili Liu,et al. Targeted Modulation of MGMT: Clinical Implications , 2006, Clinical Cancer Research.
[19] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[20] E. Shaw,et al. Reexamining the radiation therapy oncology group (RTOG) recursive partitioning analysis (RPA) for glioblastoma multiforme (GBM) patients , 2003 .
[21] Laurent Capelle,et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas , 2003, Annals of neurology.
[22] J. Murray,et al. Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy , 2002, British Journal of Cancer.
[23] J. Murray,et al. A quantitative model for differential motility of gliomas in grey and white matter , 2000, Cell proliferation.
[24] J. Allay,et al. Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells. , 1995, Blood.
[25] D. Louis,et al. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? , 2013, Nature Reviews Clinical Oncology.
[26] D. Karnofsky. The clinical evaluation of chemotherapeutic agents in cancer , 1949 .
[27] Colin M. MacLeod,et al. Evaluation of chemotherapeutic agents , 1949 .